Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
Luca Gianni(Fondazione Michelangelo), Giuseppe Viale(University of Milan)
Cited by 382
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
HER2-Low Breast Cancer: Pathological and Clinical Landscape
|Journal of Clinical Oncology|2020|801
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
|The Lancet Oncology|2021|355
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
|Modern Pathology|2015|317